PAP
NBIX icon

Persistent Asset Partners’s Neurocrine Biosciences NBIX Stock Holding History

Persistent Asset Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.2K Buy
+440
New +$65.3K 0.02% 354
2025
Q4 		– Sell
-8,694
Closed -$1.22M – 417
2025
Q3 		$1.22M Sell
8,694
-12,931
-60% -$1.75M 0.84% 34
2025
Q2 		$2.72M Buy
21,625
+7,321
+51% +$840K 2.02% 11
2025
Q1 		$1.58M Buy
14,304
+3,560
+33% +$451K 1.33% 22
2024
Q4 		$1.63M Buy
+10,744
New +$1.33M 1.35% 21

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Persistent Asset Partners's NBIX Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 440 shares worth $74.2K. The stake represents 0.02% of the portfolio and ranks #354 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in NBIX as recently as Q3 2025.

Persistent Asset Partners first reported a position in NBIX in Q4 2024 and has held it in 5 quarters since. The position peaked at $2.72M in Q2 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Persistent Asset Partners held 440 shares of Neurocrine Biosciences worth $74.2K as of Q2 2026.
  • Neurocrine Biosciences was a new Persistent Asset Partners position in Q2 2026.
  • Neurocrine Biosciences made up 0.02% of Persistent Asset Partners's portfolio in Q2 2026, its #354 holding.
  • Persistent Asset Partners first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 5 quarters since.
  • Persistent Asset Partners's Neurocrine Biosciences position peaked at $2.72M in Q2 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.